<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780490</url>
  </required_header>
  <id_info>
    <org_study_id>2018/374</org_study_id>
    <nct_id>NCT04780490</nct_id>
  </id_info>
  <brief_title>Comparison of Liberal and Restrictive Fluid Management on the Endothelial Glycocalyx in Radical Cystectomy</brief_title>
  <official_title>Comparison of the Effects of Perioperative Liberal and Restrictive Fluid Management on the Endothelial Glycocalyx Layer in Radical Cystectomy and Urinary Diversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of the liberal and restrictive fluid&#xD;
      treatments which are routinely performed in major urological surgeries in the perioperative&#xD;
      period on ANP release and the endothelial glycocalyx layer.&#xD;
&#xD;
      In the study, the investigators aimed to compare changes in the glycocalyx structure by&#xD;
      measuring the blood levels of ANP and heparan sulfate, hyaluronan and syndecan 1, which form&#xD;
      the glycocalyx structure on the patients who received the liberal and restrictive fluid&#xD;
      treatments during major urological surgeries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no strong evidence about the optimal fluid resuscitation for the patients undergoing&#xD;
      major surgeries. Avoiding excess fluid resuscitation in the perioperative period is essential&#xD;
      for reducing postoperative complications, morbidity and long-term mortality. In the&#xD;
      perioperative period, ANP is released with increased wall stress in the cardiac atrium due to&#xD;
      excess fluid loading. With the release of ANP, damage occurs in the glycocalyx layer, which&#xD;
      is the structure primarily responsible for the permeability in the vascular endothelium.&#xD;
&#xD;
      Thus, the amount of ANP released from atrium and heparan sulfate, syndecan 1, hyaluronan in&#xD;
      the glycocalyx layer structure increases in the blood.&#xD;
&#xD;
      The aim of this study is to compare changes in the glycocalyx structure by measuring the&#xD;
      blood levels of ANP and heparan sulfate, hyaluronan and syndecan 1, which form the glycocalyx&#xD;
      structure on the patients who received the liberal and restrictive fluid treatments during&#xD;
      major urological surgeries. The blood samples will be taken at the beginning and at the end&#xD;
      of the surgery.&#xD;
&#xD;
      The primary outcome of this study is the increase in ANP levels and heparan sulfate ,&#xD;
      hyaluronic acid, syndecan 1 levels which are the glycocalyx damage products in blood.&#xD;
&#xD;
      Secondary outcomes are intraoperative advanced hemodynamic cardiac measurement values, the&#xD;
      amount of blood and blood products replaced to patients, duration of intensive care stay,&#xD;
      duration of hospital stay, cardiac and respiratory complications, gastrointestinal&#xD;
      complications, urinary complications, surgical complications such as anastomotic leaks, wound&#xD;
      infection and fistula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial Natriuretic Peptide (ANP)( pg/mL)</measure>
    <time_frame>The blood sample will be taken at beginning and end of the surgery</time_frame>
    <description>Blood ANP concentration will be determined using an enzyme-linked immunosorbent assay kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heparan sulfate (ng/L)</measure>
    <time_frame>The blood sample will be taken at beginning and end of the surgery</time_frame>
    <description>Blood Heparan sulfate concentration will determine using an enzyme-linked immunosorbent assay kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Syndecan 1 (pg/mL)</measure>
    <time_frame>The blood sample will be taken at beginning and end of the surgery</time_frame>
    <description>Blood Syndecan 1 concentration will be determined using an enzyme-linked immunosorbent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyaluronan (ng/L)</measure>
    <time_frame>The blood sample will be taken at beginning and end of the surgery</time_frame>
    <description>Blood Hyaluronan concentration will be determined using an enzyme-linked immunosorbent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of blood transfusion (unit)</measure>
    <time_frame>From the beginning surgery to day 2 postoperatively</time_frame>
    <description>Including red cell, fresh frozen plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total intensive care unit (ICU) stay (Hour, day)</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Including initial ICU admission and readmission times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay (Hour, day)</measure>
    <time_frame>90 days postoperative</time_frame>
    <description>From the beginning of surgery until actual hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complications</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Ileus, constipation, gastrointestinal bleeding, gastric ulcer, anastomotic intestinal leakage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Urinary tract infection, pyelonephritis, urosepsis, pneumonia, wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site complications</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Wound dehiscence, evisceration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genitourinary complications</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Acute kidney injury, urethral anastamosis leak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac complications</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>Acute myocardial infarction, congestive heart failure, arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>30 days postoperative</time_frame>
    <description>pulmonary embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume Variation (SVV)(%)</measure>
    <time_frame>From onset of the surgery up to end of the surgery, every 30 minutes</time_frame>
    <description>SVV will be measured with Flo-Trac system (Edward Life Sciences). Normal range is about %10-15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index(CI )(l min-1 m-2),</measure>
    <time_frame>From onset of the surgery up to end of the surgery, every 30 minutes</time_frame>
    <description>CI will be measured with Flo-Trac system (Edward Life Sciences). Normal value is 2,6-4,2 l min-1 m-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance Index (SVRI )(dyn*s.cm-5 )</measure>
    <time_frame>From onset of the surgery up to end of the surgery, every 30 minutes</time_frame>
    <description>SVRI will be measured with Flo-Trac system (Edward Life Sciences). Normal value is about 900-1300 dyn*s.cm-5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Fluid Retention Tissue</condition>
  <arm_group>
    <arm_group_label>liberal fluid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine (No medication from the epidural catheter will be administered during surgery).&#xD;
Standard anesthesia induction will be applied (fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ), and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.&#xD;
Fluid resuscitation will be started with 10 ml / kg / hr Ringer's lactate solution.&#xD;
In patients with MAP &lt;65 mmHg, 250 ml of Ringer's lactate solution will be given as a bolus.&#xD;
If the hypotension persists, the bolus 250 ml Ringer's lactate solution will be repeated up to 10 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>restrictive fluid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine ( No medication from the epidural catheter will be administered during surgery. ) Standard anesthesia induction will be applied ( fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ) and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.&#xD;
Fluid resuscitation will be started with 2 ml / kg / hr Ringer's lactate solution and norepinephrine infusion at a dose of 2 mcg / kg / hr.&#xD;
In patients with MAP&lt;65 mmHg, norepinephrine dose will be increased up to 8 mcg / kg / hr.&#xD;
If the hypotension persists although the norepinephrine dose is 8 mcg / kg / hr, 250 ml bolus Ringer's lactate solution will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liberal fluid management</intervention_name>
    <description>10 ml/ kg/ hr Ringer's lactate solution</description>
    <arm_group_label>liberal fluid therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>restrictive fluid management</intervention_name>
    <description>2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion</description>
    <arm_group_label>restrictive fluid therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA (The American Society of Anesthesiologists) status I-II-III patients&#xD;
&#xD;
          -  Cases undergoing major urological surgery&#xD;
&#xD;
          -  Cases for invasive artery monitoring and central venous catheterization&#xD;
&#xD;
          -  Patients receiving general anesthesia&#xD;
&#xD;
          -  Volunteering to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Patients with severe heart, kidney and liver dysfunction (EF &lt;35% and / or GFR &lt;30,&#xD;
             Cre:&gt; 2.5 and / or impaired liver function tests)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meltem Savran KARADENİZ</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Burcu Kulaksiz Mammadov, MD</last_name>
    <phone>+905447361952</phone>
    <email>burcukulaksiz@istanbul.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meltem Savran Karadeniz, Assoc. Prof</last_name>
    <phone>+902124142153</phone>
    <email>mskaradeniz@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burcu Kulaksiz Mammadov, MD</last_name>
      <phone>+905447361952</phone>
      <email>burcukulaksiz@istanbul.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Meltem Savran Karadeniz, Assoc. Prof</last_name>
      <phone>+902124142153</phone>
      <email>mskaradeniz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/23887199</url>
    <description>Restrictive deferred hydration combined with preemptive norepinephrine infusion during radical cystectomy reduces postoperative complications and hospitalization time: a randomized clinical trial.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/25497357</url>
    <description>Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/22290457</url>
    <description>Revised Starling equation and the glycocalyx model of transvascular ﬂuid exchange: an improved paradigm for prescribing intravenous ﬂuid therapy</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Meltem Savran Karadeniz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>peroperative fluid management</keyword>
  <keyword>restrictive fluid therapy</keyword>
  <keyword>endothelial glycocalyx</keyword>
  <keyword>Liberal fluid therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

